Home > Dermatology > EADV 2022 > Baricitinib: a possible treatment option for children with AD?

Baricitinib: a possible treatment option for children with AD?

Presented By
Dr Antonio Torrelo, Hospital Infantil Universitario Niño Jesús, Spain
Conference
EADV 2022
Trial
Phase 3, BREEZE-AD-PEDS
Children that were treated with various dosages of baricitinib for atopic dermatitis (AD) showed significant amelioration in the high dose study arm, according to the BREEZE-AD-PEDS study. A rate of 41.7% achieved a validated Investigator’s Global Assessment (vIGA) of clear or almost clear score. In the phase 3 BREEZE-AD-PEDS trial (NCT03952559), 483 patients aged 2 to <18 years were randomised to 4 study arms, receiving baricitinib either at a low, medium, or high dose, or placebo [1]. Dose regimens were adjusted to <10 years or 10 to <18 years, with daily 0.5 mg/1 mg, 1 mg/2 mg, or 2 mg/4 mg baricitinib. A vIGA of clear or almost clear (0/1) score with at least 2-point improvement from baseline, marked the primary endpoint at week 16. To be included, the patient needed to have moderate-to-severe AD with a history of inadequate response or intolerance of...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on